The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Practical Aspects of the Ligand-Binding and Enzymatic Properties of Human Serum Albumin.
Open accessAbstract
Recent work with approaches like recombinant mutants and X-ray crystallography has given much new information about the ligand-binding properties of human serum albumin (HSA). The information increases the understanding of this unique transport and depot protein and could give a structural basis for the possible construction of therapeutic agents with altered HSA-binding properties. A tabulation of high-affinity binding sites for both endogenous and exogenous compounds has been made; it could be useful for the above-mentioned purpose, but it could also be of value when trying to predict potential drug interactions at the protein-binding level. Drug displacement is not always a complication to therapy; it can be used to increase the biological effect of a drug. However, due to rebinding at other sites, the increase in the free concentration of a displaced ligand can be less than expected. Drugs and drug metabolites can also interact covalently with HSA; thiol-containing drugs often bind to the single free cysteine residue of HSA, and glucuronidated drugs react irreversibly with other residues of the protein. Reversible binding of ligands is often stereospecific, and therefore immobilized HSA can be used to separate drug isomers. Albumin-containing dialysates are useful for extracorporeal removal of endogenous toxins and in the treatment of drug overdoses. HSA has different types of hydrolytic activities, which also can be stereospecific. The esterase-like property seems especially useful in converting prodrugs to active drugs in plasma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atomic structure and chemistry of human serum albumin
He, X. M., & Carter, D. C. (1992) · Nature · doi:10.1038/358209a0 · Cited by 3,824
All About Albumin: Biochemistry, Genetics, and Medical Applications
Peters, T. (1995) · Thammasat University Digital Collections · Cited by 3,372
Carter, D. C., & Ho, J. X. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60640-3 · Cited by 3,187
Crystal structure of human serum albumin at 2.5 Å resolution
Sugio, S., Kashima, A., Mochizuki, S., Noda, M., & Kobayashi, K. (1999) · Protein Engineering, Design and Selection · doi:10.1093/protein/12.6.439 · Cited by 1,786
The Characterization of Two Specific Drug Binding Sites on Human Serum Albumin
SUDLOW, G., BIRKETT, D. J., & WADE, D. N. (1975) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10691-3 · Cited by 1,725
Molecular aspects of ligand binding to serum albumin.
Kragh-Hansen, U. (1981) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06849-8 · Cited by 1,544
Self-citationCurry, S., Mandelkow, H., Brick, P., & Franks, N. (1998) · Nature Structural Biology · doi:10.1038/1869 · Cited by 1,377
Bhattacharya, A. A., Grüne, T., & Curry, S. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4158 · Cited by 905
Crystal Structure Analysis of Warfarin Binding to Human Serum Albumin
Petitpas, I., Bhattacharya, A. A., Twine, S., East, M., & Curry, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100575200 · Cited by 825
Mitzner, S. R., Stange, J., Klammt, S., Risler, T., Erley, C. M., Bader, B. D., Berger, E. D., Lauchart, W., Peszynski, P., Freytag, J., et al. (2000) · Liver Transplantation · doi:10.1002/lt.500060326 · Cited by 717
Cited by
Human serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
The extraordinary ligand binding properties of human serum albumin
Fasano, M., Curry, S., Terreno, E., Galliano, M., Fanali, G., Narciso, P., Notari, S., & Ascenzi, P. (2005) · IUBMB Life (International Union of Biochemistry and Molecular Biology: Life) · doi:10.1080/15216540500404093 · Cited by 1,086
Albumin: Biochemical properties and therapeutic potential†
Quinlan, G. J., Martin, G. S., & Evans, T. W. (2005) · Hepatology · doi:10.1002/hep.20720 · Cited by 984
On the Value of c: Can Low Affinity Systems Be Studied by Isothermal Titration Calorimetry?
Turnbull, W. B., & Daranas, A. H. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036166s · Cited by 725
Albumin-based drug delivery: harnessing nature to cure disease
Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016) · Molecular and Cellular Therapies · doi:10.1186/s40591-016-0048-8 · Cited by 683
Protein–surfactant interactions: A tale of many states
Otzen, D. (2011) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.03.003 · Cited by 637
Harnessing albumin as a carrier for cancer therapies
Hoogenboezem, E. N., & Duvall, C. L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.011 · Cited by 610
Li, B., Sedlacek, M., Manoharan, I., Boopathy, R., Duysen, E. G., Masson, P., & Lockridge, O. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.09.002 · Cited by 540
Sridhar, R., Lakshminarayanan, R., Madhaiyan, K., Amutha Barathi, V., Lim, K. H. C., & Ramakrishna, S. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00226a · Cited by 519
Sinapic Acid and Its Derivatives: Natural Sources and Bioactivity
Nićiforović, N., & Abramovič, H. (2014) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12041 · Cited by 511
Rabbani, G., & Ahn, S. N. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.11.053 · Cited by 505
Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications
Garcia-Martinez, R., Caraceni, P., Bernardi, M., Gines, P., Arroyo, V., & Jalan, R. (2013) · Hepatology · doi:10.1002/hep.26338 · Cited by 471
Albumin–drug interaction and its clinical implication
Yamasaki, K., Chuang, V. T. G., Maruyama, T., & Otagiri, M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.05.005 · Cited by 464
Self-citationThe glycation of albumin: Structural and functional impacts
Rondeau, P., & Bourdon, E. (2011) · Biochimie · doi:10.1016/j.biochi.2010.12.003 · Cited by 433
Current issues in measurement and reporting of urinary albumin excretion
Miller, W. G., Bruns, D. E., Hortin, G. L., Sandberg, S., Aakre, K. M., McQueen, M. J., Itoh, Y., Lieske, J. C., Seccombe, D. W., Jones, G., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.106567 · Cited by 381
Lindman, S., Lynch, I., Thulin, E., Nilsson, H., Dawson, K. A., & Linse, S. (2007) · Nano Letters · doi:10.1021/nl062743+ · Cited by 377
Interactive Association of Drugs Binding to Human Serum Albumin
Yang, F., Zhang, Y., & Liang, H. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033580 · Cited by 376
“metals and toxic metabolites [1–6].”
Recent trends in protein and peptide-based biomaterials for advanced drug delivery
Varanko, A., Saha, S., & Chilkoti, A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.008 · Cited by 369
Oettl, K., & Stauber, R. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707251 · Cited by 357
Ahmed, N., Dobler, D., Dean, M., & Thornalley, P. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410973200 · Cited by 314
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging
Kompella, U. B., Amrite, A. C., Pacha Ravi, R., & Durazo, S. A. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.04.001 · Cited by 258
Poulin, P., Kenny, J. R., Hop, C. E. C. A., & Haddad, S. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22792 · Cited by 109
Metadata
- Authors
- Kragh-Hansen, U., Chuang, V. T. G., & Otagiri, M.
- Venue
- Biological and Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2002
- Volume
- 25
- Issue
- 6
- Pages
- 695-704
- ISSN
- 0918-6158 (ISSN-L)
- 1347-5215
- OpenAlex
- W2088900329
- Cited by
- 892
- References
- 48
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.